Hepatocellular Cancer Clinical Trial
Official title:
Pilot Study of Real Time MR Temperature Monitoring of Multipolar Radiofrequency Ablation of Large Hepatocellular Carcinomas (≥ 5 CM)-ARMTICH STUDY
Object of the study:
To assess the effectiveness of MR temperature monitoring of RFA of large hepatocellular
carcinomas (HCC) (≥ 5 cm) in terms of complete tumor necrosis rate achieved and in term of
reduction of the number of procedure required to obtain complete ablation of the tumors.
Experimental plan :
This pilot study consist to perform in a single center a single procedure of the multipolar
RF ablation under MR temperature monitoring for the treatment of up to three HCC with
diameter ranging from 5 cm and 10 cm in 20 inoperable patients. The main judgement criterion
of the study will be the rate of complete ablation one month after one RFA procedure
performed under MR temperature monitoring. The secondary criteria are, the 2-years local
recurrence rate (after the first initial RF ablation procedure performed under MR temperature
imaging ± additional RF ablation procedures under ultrasound monitoring in case of remnant
viable foci of tumor), the potential reduction of the number of RF procedures required to
achieve complete necrosis and the complication rate of RF ablation procedure performed under
MR temperature monitoring.
In exploratory attempt, the study will include comparative assessment of these criteria with
a historic leg of patients previously treated by the same operator in the same center for
similar large tumor by multipolar RFA but using exclusively ultrasound monitoring.
The RF procedure and results assessment:
1. In preparing MR room, the patient will be positioned on MR bed put on dedicated MR
compatible trolley. The abdominal antenna will be installed.
2. General anesthesia with tracheal intubation will be performed.
3. Up to six RF electrodes (up to 6 depending on the size and the location of the tumor)
will be inserted under ultrasound guidance.
4. The patient will be translated without any direct manipulation in the magnet.
5. With usual T1 and T2 weighted MR morphologic sequences the poisoning of electrode will
be checked and if necessary adjusted
6. Adjustment or MR temperature imaging (before RF energy deposition)
7. Starting of RF procedure under MR temperature monitoring
8. According to thermal dose maps data repositioning of electrodes and complementary energy
deposition if necessary
9. Hot withdrawal of electrodes
10. Immediate (T0) post procedure MR assessment of the limits of ablation zone (T2 SPIRCHOL,
Diffusion B600, In out phase, THRIVE dynamic after intravenous gadolinium injection).
After the procedure patients will be monitored at least 48 h.
MR assessment of treatment response will be performed one month after the procedure (same MR
protocol performed at T0).
If the ablation is complete follow up will be ensured by MR every three months. If the
ablation appeared incomplete or in case of recurrence additional RF ablation will be
performed if the patient stills met the criteria of the treatment. The eventual additional RF
ablation will be performed under ultrasound monitoring (the response to each additional RF
ablation procedure will be assessed by MR one month after).
At the end of the study patients for whom complete radiological response of the tumor(s)
initially treated (not local or distance recurrences) will be never achieved, will be
considered in treatment failure.
Local recurrence is defined as the reappearance of viable tumor in contact of ablation zone
of a tumor considered at least on one MR post therapeutic examination as completely ablated.
All the adverse effect and complication will be recorded and reported.
Quantitative analysis of 2D and 3D parameters of tumors and their related ablation zones as
observed at the end of RF procedures on temperature maps using thermal dose concept (as
previously extensively investigated) and with usual morphologic MR imaging (all used
sequences) before, during and after the procedure (one month after) will be recorded and
compared.
Antibioprophylaxy: will be prescribed in patients with an antecedent of endoscopic
sphincterotomy (according to the CLIN protocol of Jean Verdier Hospital) and will be extended
in patients : 1 older than 75 years , 2 patient with vesicular lithiasis 3) patients with
nodule previously treated by embolization and those with a severe diabetes
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03971201 -
A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion
|
Phase 2 | |
Recruiting |
NCT04484636 -
PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)
|
N/A | |
Recruiting |
NCT05489250 -
The PLATON Network
|
||
Completed |
NCT01967823 -
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
|
Phase 2 | |
Terminated |
NCT00878215 -
Clinical Application of Image-Guided Liver Surgery
|
Phase 2 | |
Completed |
NCT04212286 -
Comparing the Diagnostic Efficiencies of CEUS and EOB-MRI in Patients With High Risk of HCC
|
N/A | |
Recruiting |
NCT05992220 -
Atezolizumab Plus Bevacizumab Alone or Combined With External Beam Radiotherapy for HCC With Macrovascular Invasion
|
Phase 2 | |
Completed |
NCT02073435 -
A2ALL-Patients Safety System Improvements in Living Donor Liver Transplantation
|
||
Active, not recruiting |
NCT01522937 -
A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer
|
Phase 2 | |
Terminated |
NCT05061537 -
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT04166240 -
Measuring and Improving the Safety of Test Result Follow-Up
|
N/A | |
Withdrawn |
NCT02288507 -
Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer
|
Phase 1 | |
Terminated |
NCT03026803 -
A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04682847 -
Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
|
||
Active, not recruiting |
NCT05100082 -
Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma
|
||
Active, not recruiting |
NCT03195699 -
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers
|
Phase 1 | |
Completed |
NCT02616692 -
HCC Patient Preferences in Japan
|
N/A | |
Active, not recruiting |
NCT03132792 -
AFPᶜ³³²T in Advanced HCC
|
Phase 1 | |
Recruiting |
NCT01849588 -
Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C
|
Phase 4 | |
Suspended |
NCT00909558 -
Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer
|
Phase 1 |